#Novo has agreed to pay up to $2.6bn for rights to a weight-loss pill, developed by China's #Hengrui Pharma, that could be dosed just once a week.
@pharmaphorum.bsky.socialExplore
@pharmaphorum.bsky.social@pharmaphorum.bsky.socialJiangsu #Hengrui Pharma's oral thrombopoietin (#TPO) receptor agonist #hetrombopag has been approved in #China to treat low platelet counts (thrombocytopenia) caused by #chemotherapy for #solidtumours.
